VINSELSPITAL UNIVERSITÄTSSPITAL BERN HÔPITAL UNIVERSITAIRE DE BERNE

Sommerstein Rami MD¹, Andrew Atkinson MSc¹, Elia Lo Priore¹, Marschall Jonas MD¹, Kronenberg Andreas MD^{1,2} and the Swiss Centre for Antibiotic resistance (ANRESIS) ¹ Department of Infectious Diseases, Bern University Hospital, Switzerland; ² Institute for Infectious Diseases, University of Bern, Switzerland

Recommendations for empirical antibiotic therapy of hospital-acquired pneumonia are currently based on local susceptibility patterns of commonly detected pathogens, patient characteristics and length of hospital stay. However, the influence of length of stay on antimicrobial resistance has not been systematically studied.



(Bottom, Right).

The current concept of early versus late hospital-acquired pneumonia implies that antimicrobial resistance develops in a biphasic manner and assumes length of stay is a crucial predictor. Our findings suggest a more complicated picture: Overall resistance development is i) the result of a shift towards more resistant species, ii) an overlap of distinct resistance evolution patterns for individual species (monophasic or biphasic), and iii) dependent on sampling methods, environmental and host factors. As increasing resistance was not observed for all antibiotics, length of stay appears not to be the primary contributor. These findings question the current clinical classification as a guide for choosing empirical antibiotics for hospital-acquired pneumonia.

Abbreviation: TMPSX, Trimethoprim / Sulfamethoxazol; BLI, Beta Lactamase Inhibitor; Gen Ceph, Generation Cephalosporine

Resistance Evolution in Respiratory Tract Pathogens During Hospitalization (P1052)

Using data from the Swiss Antibiotic Resistance Surveillance System (anresis.ch), antimicrobial resistance testing results from patients hospitalized between 2008-2014 were compiled and stratified for length of stay, sampling method, environmental (ward type, type of referral center, linguistic region) and host factors (age, sex). General additive and general linear models were applied to illustrate resistance odds.

Pseudomonas aeruginosa. The corresponding 95% confidence intervals are grey-shaded.



| | 0.65- | 0.65- 0.60- 0.60- 0.55- 0.50- <t< th=""></t<> | | | | |
|--|---|---|--|---|---|--|
| Antibiotic Oxacillin Penicillin TMPSX | 0.60- 0.55- 0.50- 20 0.45- | | | | | |
| | b 0.40 b 0.35 c 0.35 c 0.30 c 0.30 c 0.25 c 0. | | | | 3rd_4th_0 Aminogly · · · · · Quinolone | |
| | 0.20- 0.15- 0.10- 0.05- 0 2 4 6 8 1 | 0 12 14 1 | 6 18 20 22 | 24 26 28 | 30 | |
| | | Days since hospita | lisation | | | |
| | Overall Resistance rate for resp | piratory tract is | olates | | | |
| | Overall Resistance rates per hos | spitalization day | y for important | antibiotics or a | ntibiotic group | |
| | nrimary isolates with testing av | ailable (lines) w | vere calculated a | and displayed b | v using a gener | |
| Antibiotic ····· 3/4_Gen_Ceph | linear model. The correspondin | a 95% confider | ce intervals are | grov-shaded | y doing a gene | |
| · Aminogiycoside · Amoxicillin_BLI Chinolone | intear model. The correspondin | g 5570 connuer | | grey-snaueu. | | |
| | | Amoxicillin_BLI | Aminoglycoside | 3/4 Gen Ceph | Chinolone | |
| | Samples (n) | 24,765 | 24,759 | 23,641 | 28,325 | |
| | Background | 0 467*** (0 422 0 502) | 0.066*** (0.0590.075) | 0 112*** (0 102 0 126) | | |
| 28 30 | Increase in resistance odds / day | 1.065*** (1.056, 1.075) | 1 038*** (1 025 1 051) | 1.063*** (1.054 1.072) | 1 031*** (1 020 1 042) | |
| | Recovery method = BAL | | 1.050 (1.025, 1.051) | 1.005 (1.054, 1.072) | 1.051 (1.020, 1.042) | |
| | Odds of increase in resistance compared to background | 0.760** (0.644, 0.894) | 1.125 (0.877, 1.430) | 1.047 (0.821, 1.323) | 0.922 (0.729, 1.156) | |
| | Increase in resistance odds / day compared to background | 1.025** (1.006, 1.045) | 1.033** (1.010, 1.056) | 1.022 (0.999, 1.046) | 1.037*** (1.015, 1.058) | |
| | Age > 60 | | | | | |
| | Odds of increase in resistance compared to background | 1.497*** (1.391, 1.611) | 0.721*** (0.641, 0.811) | Not in final model | 0.881* (0.787, 0.985) | |
| Antibiotic | Increase in resistance odds / day compared to background | 0.991* (0.983, 0.999 | 1.014* (1.003, 1.026) | Not in final model | 1.021*** (1.010, 1.032) | |
| 28 30 | Unit Type = ICU | | | | | |
| | Odds of increase in resistance compared to background | 1.058 (0.984, 1.139) | 1.966***(1.743, 2.221) | 1.100 (0.980, 1.235) | 1.652*** (1.472, 1.854) | |
| | Increase in resistance odds / day compared to background | 0.978*** (0.970, 0.986) | 0.969***(0.958, 0.980) | 0.982** (0.972, 0.993) | 0.968***(0.958, 0.978) | |
| | Sex = Female | Not in final model | 1 106*** (1 004 1 206) | 1 000 /0 000 1 107) | 1 100*** /1 002 1 204) | |
| | Increase in resistance odds / day compared to background | Not in final model | Not in final model | 1.069 (0.998, 1.187) Not in final model | Not in final model | |
| | Tertiary Referral Center = ves | | | | | |
| 50 | | 0.749*** (0.694, 0.809) | 1.131* (1.002, 1.276) | 0.715*** (0.659, 0.776) | 0 644*** (0 593 0 700) | |
| 5 50 | Odds of increase in resistance compared to background | | | · · · · · · · · · · · · · · · · · · · | (0.333, 0.700) | |
| 50 | Odds of increase in resistance compared to background Increase in resistance odds / day compared to background | 0.987** (0.979, 0.996) | 0.975*** (0.964, 0.986) | Not in final model | Not in final model | |
| | Odds of increase in resistance compared to background Increase in resistance odds / day compared to background Linguistic Region = Latin Languages | 0.987** (0.979, 0.996) | 0.975*** (0.964, 0.986) | Not in final model | Not in final model | |
| | Odds of increase in resistance compared to background Increase in resistance odds / day compared to background Linguistic Region = Latin Languages Odds of increase in resistance compared to background | 0.987** (0.979, 0.996) Not in final model | 0.975*** (0.964, 0.986) 1.139* (1.010, 1.283) | Not in final model 0.785*** (0.695, 0.885) | Not in final model 1.336*** (1.195, 1.494) | |

The 95% confidence intervals are in brackets.

Schweizerisches Zentrum für Antibiotikaresistenzen